Y-Biologics KRX:338840KOSDAQ
와이바이오로직스 · Korean news coverage and regulatory filings, organized.
In Q3 2026, Y-Biologics reported revenue of ₩292m, down 67.3% year on year, and an operating loss of ₩5.1bn. Y-Biologics (와이바이오로직스) appeared in 2 Korean news articles and 2 DART filings over the past seven days. Coverage peaked on Nov 5 with 6 articles. The most common catalyst was contracts & orders (3). It was most often mentioned alongside 글로벌테크놀로지, Curocell and GI Innovation.
Filing signals Insider buying 4 quarters of losses Screener
Y-Biologics at a glance from DART filings
- Results trend
- Operating loss in each of the last 4 quarters; Q3 2026 operating loss of ₩5.1bn a loss again after the previous quarter.
- Ownership changes
- 11 5%-holder and insider ownership reports in the past 120 days (9 increases, 2 decreases).
Figures the company filed on DART, grouped by ATS View. Not a buy or sell call; see the cards below and the DART originals.
Y-Biologics today: up or down?
No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.
Upcoming dates as filed
- Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026
Dates Y-Biologics stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.
Y-Biologics quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q3 2026 | ₩292m | -67.3% | −₩5.1bn | −₩5.8bn |
| Q2 2026 | ₩1.5bn | +32.8% | −₩3.8bn margin −244.9% | −₩7.8bn |
| Q1 2026 | ₩282m | -30.8% | −₩3.9bn | −₩4.3bn |
| Q4 2025 derived | ₩449m | -60.9% | −₩3.0bn | −₩35.1bn |
| Q3 2025 | ₩892m | -72.5% | −₩2.5bn margin −283.5% | −₩2.7bn |
| Q2 2025 | ₩1.2bn | +402.0% | −₩1.5bn margin −128.4% | −₩2.3bn |
| Q1 2025 | ₩407m | -64.4% | −₩2.3bn | −₩1.9bn |
| Q4 2024 derived | ₩1.1bn | +86.2% | −₩2.4bn margin −205.9% | −₩1.8bn |
Y-Biologics ranks #2211 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Y-Biologics top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest Y-Biologics news Korean headlines
-
Y Biologics to present two multi-app kine research studies at US SITC
9 more on this story · 8 outlets
- Y Biologics presents two multi-app kine research posters at US SITC 2026더바이오 · Oct 20 08:31
- Y Biologics presents two preclinical multi-app kine achievements at SITC한국경제 · Oct 20 08:31
- Wibio Logistics presents two 'Multi-AppCine' research studies at SITC2026뉴스핌 · Oct 20 09:32
- Wyeth Biologics to present 2 multi-cytokine research results at U.S. immunotherapy conference이데일리증권 · Oct 20 09:41
- Wyeth Biologics to present 2 multi-cytokine research results at U.S. immunotherapy conference이데일리 · Oct 20 09:41
- Wyeth Biologics to present 2 multi-cytokine research results at U.S. immunotherapy conference이데일리 · Oct 20 09:43
- Y Biologics presents preclinical results of multiapain at US SITC컨슈머타임스 · Oct 20 09:51
- WiBio Therapeutics presents 2 multi-app canine research posters at U.S. SITC 2026스페셜타임스 · Oct 20 10:26
- Y Biologics unveils two immuno-oncology studies at U.S. SITC...first patient-derived data presentation메디컬투데이 · Oct 20 15:21